Mode
Text Size
Log in / Sign up
N/A N=20 Randomized Double-blind Treatment

A Pilot Study of TMS Effects on Pain and Depression in Patients With Fibromyalgia

Major Depression · Fibromyalgia

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Jul 2018
Primary outcome: Primary: Average Pain — 5.60; 5.43; 4.90; 5.49 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Active TMS (Device); Sham TMS (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Medical University of South Carolina
Primary completion
Oct 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Average Pain
5.60; 5.43; 4.90; 5.49; 3.99; 5.07
PRIMARY
THE FIBROMYALGIA IMPACT QUESTIONNAIRE (FIQ)-Modified
58.79; 54.38; 55.03; 51.22; 42.07; 51.50
PRIMARY
THE HAMILTON DEPRESSION RATING SCALE (HRDS)
21.80; 17.60; 17.30; 17.40; 16.10; 15.30

Summary

In this pilot study, the PI proposes to include 20 African American participants with Fibromyalgia to explore the effect of r TMS on pain and depressive symptoms.

Eligibility Criteria

Inclusion Criteria

  • age 18-80,
  • meet ACR criteria for FM for more than 6 months,
  • may or may not have a diagnosis of major depressive disorder (not bipolar) past or present,
  • Current major depressive episode must be without psychotic features
  • Not be on medication known to increase risk of TMS-induced seizures
  • No prescription medication changes in the previous 4 weeks with agreement not to change during the treatment course (2 weeks) and 2 weeks thereafter
  • No history of epilepsy or stroke or recent head trauma (LOC > 5 minutes) within the past 6 months
  • African Americans will be initially sought out for study, however the recruitment may extend to include Caucasian and Hispanic subjects to carry out the study.

Exclusion Criteria

  • Primary, current diagnosis of schizophrenia
  • Other (non-mood disorder) psychosis
  • Mental retardation
  • Substance dependence or abuse within the past 6 months (except nicotine)
  • Psychotic features in this episode, dementia, or delirium
  • Contraindication to rTMS
  • Increased intracranial pressure
  • Brain surgery, or head trauma with loss of consciousness for > 15 minutes
  • Implanted electronic device
  • Metal in the head, or pregnant
  • Has an active autoimmune, endocrine, viral, or vascular disorder affecting the brain or unstable cardiac disease
  • Uncontrolled hypertension, or severe renal or liver insufficiency
  • Unstable and active suicidal intent or plan
  • History of attempt requiring medical hospitalization within in the past 6 months
  • -currently an involuntary inpatient on a psychiatric ward.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00523302). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search